By analyzing the therapeutic heterogeneity between subgroups, we concluded that women or patients with negative PD-L1 expression or with LDH ≤ ULN or without brain metastasis tend to benefit more from first-line chemoimmunotherapy in ES-SCLC. Here, CD274 is linked to small cell lung carcinoma.